LITAF — Lipopolysaccharide-Induced Tumor Necrosis Factor Factor

LITAF — Lipopolysaccharide-Induced Tumor Necrosis Factor Factor

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">LITAF</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>LITAF</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Lipopolysaccharide-Induced Tumor Necrosis Factor Factor</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>16p13.13</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>10868</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000106789</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>604577</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9Y5K2</td>
</tr>
<tr>
<td class="label">Protein Alias</td>
<td>SIMPLE, CMT1C</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Charcot-Marie-Tooth Disease Type 1C</td>
</tr>
</table>

LITAF — Lipopolysaccharide-Induced Tumor Necrosis Factor Factor

Overview

LITAF — Lipopolysaccharide-Induced Tumor Necrosis Factor Factor

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">LITAF</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>LITAF</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Lipopolysaccharide-Induced Tumor Necrosis Factor Factor</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>16p13.13</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>10868</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000106789</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>604577</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9Y5K2</td>
</tr>
<tr>
<td class="label">Protein Alias</td>
<td>SIMPLE, CMT1C</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Charcot-Marie-Tooth Disease Type 1C</td>
</tr>
</table>

LITAF — Lipopolysaccharide-Induced Tumor Necrosis Factor Factor

Overview

LITAF (Lipopolysaccharide-Induced Tumor Necrosis Factor Factor), also known as SIMPLE (Small Integral Membrane Protein of Lysosome/Late Endosome), is a gene encoding a 161-amino acid protein involved in cellular protein quality control, lysosomal trafficking, and inflammatory signaling. Located on chromosome 16p13.13, LITAF is expressed predominantly in Schwann cells, macrophages, and other tissues involved in immune responses and peripheral nerve function["@street2003"].

Mutations in LITAF cause Charcot-Marie-Tooth disease type 1C (CMT1C), an autosomal dominant peripheral neuropathy characterized by demyelination, axonal degeneration, and progressive muscle weakness and sensory loss. The protein plays critical roles in endosomal-lysosomal trafficking, ER-associated degradation (ERAD), and regulation of inflammatory responses through TNF-alpha transcription["@lupski2006"].

Function

SIMPLE Protein Structure and Localization

LITAF encodes SIMPLE, a type I transmembrane protein localized to the lysosomal membrane and late endosome compartments. The protein contains several functional domains:

• N-terminal domain: Contains a C-terminal sorting motif (YXXΦ) critical for endosomal trafficking
• Transmembrane domain: Anchors the protein in lysosomal membranes
• C-terminal domain: Interacts with the ESCRT machinery for sorting and degradation

Role in Protein Quality Control

LITAF plays a critical role in cellular protein quality control mechanisms:

• Endosomal Sorting: SIMPLE participates in sorting ubiquitinated proteins through interaction with the ESCRT (Endosomal Sorting Complex Required for Transport) machinery. This function ensures proper delivery of membrane proteins to the lysosome for degradation[@baharoglu2015].
• ER-Associated Degradation (ERAD): LITAF contributes to ERAD pathways that retrotranslocate misfolded proteins from the ER to the cytosol for proteasomal degradation. This function is particularly important in cells with high protein folding demands, such as Schwann cells producing large amounts of myelin proteins[@morelli2008].
• Autophagy Regulation: Recent studies demonstrate that LITAF regulates autophagy in response to cellular stress, helping to clear damaged organelles and protein aggregates[@wang2019].

Transcriptional Regulation of Inflammation

LITAF functions as a transcription factor regulating inflammatory gene expression:

• TNF-α Regulation: LITAF directly binds to the TNF-α promoter and regulates its transcription. This function links LITAF to innate immune responses and inflammatory signaling pathways[@ma2018].
• NF-κB Interplay: LITAF interacts with NF-κB signaling pathways, creating crosstalk between transcriptional regulation and inflammatory responses. Dysregulation of this pathway contributes to the inflammatory features of CMT1C[@chen2021].

Lysosomal Trafficking

The lysosomal trafficking function of LITAF is central to its disease mechanism:

• Late Endosome Function: SIMPLE localizes to the late endosome/lysosome compartment where it facilitates protein sorting and trafficking
• Cargo Transport: LITAF helps coordinate the movement of cargo between endosomal compartments
• Lysosomal Biogenesis: The protein contributes to lysosomal biogenesis and function, processes critical for cellular clearance mechanisms[@zhou2020]

Disease Associations

Charcot-Marie-Tooth Disease Type 1C (CMT1C)

CMT1C is caused by dominant LITAF mutations and represents a distinct subtype within the demyelinating forms of Charcot-Marie-Tooth disease[@senderek2003]:

Clinical Features:

• Progressive distal muscle weakness and atrophy (starting in feet/legs)
• Sensory loss, particularly of vibration and proprioception
• Decreased or absent deep tendon reflexes
• Foot deformities (pes cavus, hammertoes)
• Reduced nerve conduction velocities (NCV <38 m/s in demyelinating forms)
• Variable age of onset (typically second to fourth decade)

• Segmental demyelination and remyelination
• Onion bulb formation (proliferation of Schwann cell processes)
• Axonal loss in chronic cases
• Accumulation of lysosomal debris in Schwann cells

CMT with Vocal Cord Paralysis

Some LITAF mutations are associated with additional features beyond typical CMT1C:

• Vocal cord paralysis (bilateral)
• Hoarseness
• Respiratory complications in rare cases

Inflammatory Conditions

Given its role in TNF-α regulation, LITAF has been implicated in inflammatory conditions:

• Altered LITAF expression observed in rheumatoid arthritis
• Potential modifier role in inflammatory neuropathies
• Association with autoimmune responses in some populations

Molecular Mechanisms

Lysosomal Dysfunction in CMT1C

The primary disease mechanism in CMT1C involves lysosomal trafficking defects:

ER Stress in Peripheral Neuropathy

LITAF mutations trigger ER stress responses in peripheral nerve:

• Unfolded Protein Response: Accumulation of misfolded proteins activates UPR pathways
• CHOP Induction: ER stress leads to CHOP expression, promoting apoptotic pathways
• Schwann Cell Vulnerability: Myelinating Schwann cells are particularly susceptible to ER stress due to high protein synthesis demands
• Demyelination: ER stress contributes to myelin breakdown and demyelination

Inflammation-Mediated Damage

The inflammatory component of CMT1C involves:

• TNF-α Upregulation: Elevated TNF-α contributes to inflammatory demyelination
• Macrophage Infiltration: Inflammatory cells accumulate in peripheral nerve tissue
• Cytokine Cascade: Multiple pro-inflammatory cytokines are upregulated in affected nerves
• Schwann Cell Activation: Reactive Schwann cells adopt pro-inflammatory phenotypes

Therapeutic Approaches

Current Management

CMT1C management follows standard CMT approaches:

• Physical therapy and exercise
• Orthopedic interventions (bracing, surgery)
• Pain management
• Assistive devices

Emerging Therapies

| Approach | Target | Status | Rationale |
|----------|--------|--------|-----------|
| Gene silencing | LITAF mRNA | Preclinical | Reduce mutant protein toxicity |
| ESCRT modulators | Endosomal sorting | Experimental | Correct trafficking defects |
| Autophagy enhancers | Lysosomal function | Preclinical | Boost cellular clearance |
| Anti-inflammatory | TNF-α pathway | Exploratory | Modulate inflammation |
| ER stress modulators | UPR pathways | Early research | Protect Schwann cells |

Research Directions

• Small Molecule Therapies: Screening for compounds that can restore proper lysosomal trafficking
• Gene Therapy: AAV-mediated delivery of wild-type LITAF or RNAi silencing of mutant allele
• Biomarkers: Development of biomarkers for disease progression and treatment response

See Also

• [Charcot-Marie-Tooth Disease Type 1C](/diseases/cmt1c)
• [Charcot-Marie-Tooth Disease](/diseases/charcot-marie-tooth-disease)
• [Peripheral Neuropathy](/mechanisms/peripheral-neuropathy)
• [Schwann Cells](/cell-types/schwann-cells)
• [Lysosomal Trafficking](/mechanisms/lysosomal-trafficking)
• [ER Stress](/mechanisms/er-stress-unfolded-protein-response)

External Links

• [NCBI Gene: LITAF](https://www.ncbi.nlm.nih.gov/gene/10868)
• [UniProt: Q9Y5K2](https://www.uniprot.org/uniprot/Q9Y5K2)
• [OMIM: 604577](https://omim.org/entry/604577)
• [GeneCards: LITAF](https://www.genecards.org/cgi-bin/carddisp.pl?gene=LITAF)
• [ClinVar: LITAF variants](https://www.ncbi.nlm.nih.gov/clinvar/?term=LITAF)

Pathway Diagram

The following diagram shows the key molecular relationships involving LITAF — Lipopolysaccharide-Induced Tumor Necrosis Factor Factor discovered through SciDEX knowledge graph analysis: